Chad Messer analyst

Currently out of the existing stock ratings of Chad Messer, 145 are a BUY (96.67%), 4 are a HOLD (2.67%), 1 are a SELL (0.67%).

Chad Messer

Work Performance Price Targets & Ratings Chart

Analyst Chad Messer works with a stock forecast success ratio of 39.38% fulfilled within 158.1 days on average. Previously, Chad Messer worked at NEEDHAM.

Chad Messer’s has documented 261 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on GMDA, Gamida Cell Ltd at 20-Apr-2023.

Wall Street Analyst Chad Messer

Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 9/14/2016. The price target of $47 was fulfilled within 5 days with a profit of $14.55 (44.84%) receiving and performance score of 89.68.

Average potential price target upside

AGIO Agios Pharm AKBA Akebia Ther ARQL ArQule CYTK Cytokinetics ESPR Esperion Therapeutics EXEL Exelixis GNCA Genocea Biosciences IONS Ionis Pharmaceuticals PGNX Progenics Pharmaceuticals PHAS PhaseBio Pharmaceuticals SGEN Seagen SRPT Sarepta Therapeutics VCEL Vericel Corp Ord CRMD CorMedix GTHX G1 Therapeutics MREO Mereo BioPharma Group PLC ADR AGLE Aeglea Bio Therapeutics ATHX Athersys AUTL Autolus Therapeutics Ltd SELB Selecta Biosciences GMDA Gamida Cell Ltd NXTC NextCure 

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

30

$2.3 (8.30%)

32

1 months 30 days ago

3/3 (100%)

$-2.99 (-9.06%)

224

Hold

28

$0.3 (1.08%)

32

5 months 19 days ago

6/6 (100%)

$5.51 (24.50%)

192

Buy

42

$14.3 (51.62%)

67

9 months 26 days ago

5/12 (41.67%)

$13.87 (49.31%)

213

Buy

38

$10.3 (37.18%)

40

9 months 26 days ago

0/4 (0%)

$9.87 (35.09%)

Buy

37

$9.3 (33.57%)

33

1 years 8 months 17 days ago

6/11 (54.55%)

$7.26 (24.41%)

69

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Chad Messer?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?